Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Fusidate,Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study
Details : ACG-701 (sodium fusidate) is an investigational oral antibiotic that acts against bacteria by inhibiting an important step in protein synthesis for the treatment of melioidosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : Sodium Fusidate,Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftazidime,Avibactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zidavi, which is a novel combination of ceftazidime and avibactam, a preferred treatment against OXA-48-like and Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae for pyelonephritis or Complicated Urinary Tract Infecti...
Product Name : Zidavi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : Ceftazidime,Avibactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Idera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Idera Pharmaceuticals Acquires Aceragen
Details : The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 (sodium fusidate) and ACG-801, through important 2023 clinical milestones.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Idera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Arnasi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Arnasi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2019
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2019
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftazidime
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2016
Lead Product(s) : Ceftazidime
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftazidime
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Queen's University, Belfast | Université Paris Cité | University of Dundee | University of Washington | University Hospital Heidelberg | Teagasc | Clininfo | GABO:mi | Papworth Hospital NHS Foundation Trust | KU Leuven | Assistance Publique – Hôpitaux de
Deal Size : Inapplicable
Deal Type : Inapplicable
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2015
Lead Product(s) : Ceftazidime
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Queen's University, Belfast | Université Paris Cité | University of Dundee | University of Washington | University Hospital Heidelberg | Teagasc | Clininfo | GABO:mi | Papworth Hospital NHS Foundation Trust | KU Leuven | Assistance Publique – Hôpitaux de
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2015
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : PRA Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2015
Lead Product(s) : Ceftazidime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable